Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis

Inclusion Criteria: Subjects must meet the following criteria to be enrolled in this study: 1. Male or female adult ≥ 18 years of age; 2. Diagnosis of chronic plaque-type 3. Moderate to severe plaque type psoriasis as defined at baseline by: * PASI score of 12 or greater, * PGA score of 3 or greater * BSA affected by plaque-type psoriasis of 10% or greater, 4. Able and willing to give written informed consent prior to performance of any study-related procedures Exclusion Criteria: Subjects who meet any of the following criteria will be excluded from participation in this study: 1. Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic, and/or guttate psoriasis) or drug induced psoriasis 2. Subjects with previous exposure to apremilast 3. Malignancy or history of malignancy, except for: * treated \[ie, cured\] basal cell or squamous cell in situ skin carcinomas; * treated \[ie, cured\] malignancy with no evidence of recurrence within the previous 5 years.